Cogent Biosciences, Inc. (NASDAQ: COGT) is a clinical-stage biotechnology company targeting underlying causes of genetic dysfunction that cause diseases such as cancers, autoimmune disorders and rare diseases. The Company’s lead candidate bezuclastinib (CGT9486), is a precision kinase inhibitor that inhibits the KIT D816V mutation, which...
A Clinical-stage biopharmaceutical company, Onconova Therapeutics, Inc. (NASDAQ: ONTX) is developing novel therapeutics to combat cancer. The Company is developing a pipeline of small molecule candidates that target various forms of cancers such as Solid Tumors and KRAS+ NSCLC and a RAS pathway and a...
Galera Therapeutics (NASDAQ: GRTX), a clinical–stage Biopharmaceutical Company aiming to redefine radiotherapy in cancer, announced positive interim results from a phase 1/2 trial of GC4419 or avasopasem manganese. An investigational, highly selective small molecule superoxide dismutase mimetic, GC4419 has the potential to convert superoxide to...
G1 Therapeutics (NASDAQ: GTHX) shares soared by almost 25% on the basis of news that it had a productive phase 2 meeting with the FDA for the company’s lead candidate Trilaciclib, a first-in-class myelopreservation agent that protects the bone marrow from damage by chemotherapy. The...
TG Therapeutics (NASDAQ: TGTX), a clinical stage company that is leading the innovation bandwagon in the field of novel therapies for B-cell malignancies and autoimmune diseases has had a great run at the stock market so far this year. Its stocks have almost doubled in 2019 owing...
